ArticleCell communication and signaling : CCS2026
Oligonucleotide G3T19 downregulates CD44 succinylation and inhibits astrocyte-induced glioma immune escape.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAstrocytes (ACs) play a crucial role within the immune microenvironment of glioma, facilitating its progression. Protein succinylation, a post-translational modification, may serve as a significant regulatory mechanism. SsDNA (single-chain oligonucleotide) drugs with specific sequences for the treatment of tumors have entered clinical trials with remarkable effects.
methodsG3T19 was evaluated by peroxidase-like activity assay and circular dichroism experiments. The effects of G3T19 on glioma were evaluated by flow cytometry, CCK-8, transwell migration assay, immunohistochemistry, small animal imaging, HPLC, orthotopic xenograft glioma model and human glioma organoid model. The binding of G3T19 and CD44 was examined by immunoprecipitation assay, ELONA assay, immunofluorescence, and docking conformation visualization. The effect of G3T19 on CD44 succinylation was evaluated by mass spectrometry analysis, immunoprecipitation assay, and flow cytometry.
resultsG3T19 with G-quadruplex parallel structure binds to CD44 and inhibits AC-enhanced glioma immune escape. CD44 succinylation in ACs adjacent to gliomas is enhanced at lysine 40; however, G3T19 reduces CD44 succinylation to inhibit AC-enhanced glioma immune escape. G3T19-dependent targeting of CD44 reduces NF-κB signaling, PD-L1 expression, and AC-induced glioma immune escape.
conclusionThese results confirm that G3T19 binds CD44 and downregulates CD44 succinylation, inhibits NF-κB pathway and the expression of PD-L1, inhibits AC-induced glioma immune escape. This study identifies a new anti-tumor mechanism based on the advanced structure of a functional nucleic acid that may be useful in the development of drugs for glioma immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.